Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413244 · ClinicalTrials.gov registry record · Phase 3
The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery
A Phase 3 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 3
- Development phase
- 51
- Enrollment target
NCT00413244 is a Phase 3 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 51 participants.
The verdict
NCT00413244, a Phase 3 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of the study is to find out if giving the study drug, Androgel (testosterone) as a testosterone replacement help bring the testosterone to an acceptable level and to find out if it will help improve heart condition in males with coronary artery disease (CAD) following successful percutaneous coronary intervention.
Interventions
- DRUG Placebo
- DRUG AndroGel 5 Grams
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2007-01 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00413244
The ClinicalTrials.gov registry entry for NCT00413244 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00413244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00413244 about?
NCT00413244 is a clinical study titled "The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery". The purpose of the study is to find out if giving the study drug, Androgel (testosterone) as a testosterone replacement help bring the testosterone to an acceptable level and to find out if it will help improve heart condition in males with coronary artery disease (CAD) following successful percutan...
What is the current status of trial NCT00413244?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 51 participants. The study started on 2007-01. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00413244?
The interventions under investigation include: Placebo (DRUG), AndroGel 5 Grams (DRUG).
Who is sponsoring clinical trial NCT00413244?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.